Celator Pharmaceuticals, Inc.;Oregon Health & Science University
发明人:
GORDON, Max,TARDI, Paul,TYNER, Jeffrey,MAYER, Lawrence
申请号：
EP16865052
公开号：
EP3373919A4
申请日:
2016.11.10
申请国别(地区):
EP
年份:
2019
代理人:
摘要：
Diagnostic methods for identifying cancer bearing subjects appropriate for treatment with CPX-351 include genetic and ex vivo testing of cells from a candidate subject. Combination treatment with CPX-351 and FLT-3 inhibitors improve CPX-351 uptake and toxicity.
